Table 1 Baseline characteristics of patients included in each study

BEST, 2020 [30]

Bexagliflozin 20 mg

NCT02558296

1700

64.4 (7.9)

1182 (69.5)

2.5

49.8 (13.74)

77.88 (19.5)

246 (14.5%) patients with NYHA I–III class of HF.

CANDLE, 2020 [28]

Canagliflozin 100 mg

UMIN000017669

233

68.6 (10.1)

174 (74.6)

0.5

57.6 （14.6）

NA

All patients with NYHA I–III class of HF and 42.9% with an ischemic cause.

CANVAS Program, 2017 [34]

Canagliflozin 100 mg

NCT01032629; NCT01989754

8693

63.3 (8.3)

5565 (64.0)

2.4

NA

76.5 (20.5)

6656 (65.6) patients with history of CAD, 1461 (14.4%) patients with NYHA I–II class of HF.

CHIEF-HF, 2022 [21]

Canagliflozin 100 mg

NCT04252287

448

63.4 (13.3)

247 (55.1)

0.25

NA

NA

All patients with NYHA II–III class of HF.

CREDENCE, 2019 [32]

Canagliflozin 100 mg

NCT02065791

4401

63.0 (9.2)

2907 (66.1)

2.6

NA

56.2 (18.2)

2220 (50.4%) patients with history of CVD, 652 (14.8%) patients with NYHA II–III class of HF.

DAPA-HF, 2019 [39]

Dapagliflozin 10 mg

NCT03036124

4744

66.0 (11.0)

3635 (76.6)

1.5

31.1 (6.8)

66.0(19.0)

All patients with HF, 4701 (99.1%) patients with NYHA II–III class of HF.

DECLARE-TIMI 58, 2018 [29]

Dapagliflozin 10 mg

NCT01730534

17,160

63.9 (6.8)

10,738 (62.6)

4.2

NA

86.1(21.8)

5658 (33.0%) patients with history of CAD, 1722 (10.0%) patients with NYHA II–III class of HF.

DELIVER, 2022 [20]

Dapagliflozin 10 mg

NCT03619213

6263

71.7 (9.5)

3516 (56.1)

2.3

54.2 (8.8)

61.0 (19.0)

All patients with HF, 6245 (99.7%) patients with NYHA II–III class of HF.

DETERMINE-preserved, 2021 [19]

Dapagliflozin 10 mg

NCT03877224

504

71.8 (9.4)

320 (63.5)

0.33

51.5 (10.7)

58.0 (19.9)

All patients with NYHA II–III class of HF.

ERASE, 2024 [18]

Ertugliflozin 5 mg

NCT04600921

46

65.0 (11)

42 (91)

0.93

37% (11.0)

61 (18.2)

All patients with NYHA II–III class of HF.

EMBRACE-HF, 2021 [24]

Empagliflozin 10 mg

NCT03030222

65

66.2 (13.0)

41 (63)

0.25

43.7 (16.2)

56.9 (23.3)

All patients with NYHA II–III class of HF.

EMPA-HEART, 2019 [33]

Empagliflozin 10 mg

NCT02998970

97

64 (10.5)

90 (92.7)

0.5

NA

87.0 (17.0)

All patients with history of CVD.

EMPA-ICD, 2024 [17]

Empagliflozin 10 mg

jRCTs031180120

150

75 (6.2)

125 (83.3)

0.46

45.8 (16.3)

57.7 (15.2)

All patients with history of CVD.

EMPA-REG OUTCOME, 2015 [35]

Empagliflozin 10 mg

NCT01131676

4678

63.1 (8.6)

3333 (71.2)

3.1

NA

74.0 (21.4)

5380 (75.6%) patients with history of CAD, 484 (10.3%) patients with NYHA II–III class of HF.

EMPA-REG RENAL, 2014 [37]

Empagliflozin 10 mg

NCT01164501

417

63.9 (8.6)

241 (57.8)

1

NA

53.2 (18.9)

NA.

EMPA-TROPISM, 2020 [27]

Empagliflozin 10 mg

NCT03485222

84

62 (12.1)

54 (64)

0.5

36.3 (8.0)

81.5 (21.9)

All patients with NYHA II–III class of HF.

EMPEROR-Preserved, 2021 [22]

Empagliflozin 10 mg

NCT03057951

5988

71.9 (9.5)

3312 (55.3)

2.2

54.3 (8.8)

60.6 (19.9)

All patients with HF, 5,970 (99.7%) patients with NYHA I- III class of HF.

Leiter et al, 2014 [36]

Dapagliflozin 10 mg

NCT01042977

962

63.8 (7.3)

644 (66.9)

0.6

NA

NA

All patients with history of CAD, 152 (15.8%) patients with NYHA I–III class of HF.

PRESERVED-HF, 2021 [23]

Dapagliflozin 10 mg

NCT03030235

324

70.0 (10.3)

140 (43.2)

0.25

60 (7.0)

55 (20.3)

All patients with HF, 321 (99.1%) patients with NYHA I–III class of HF.

SCORED, 2021 [26]

Sotagliflozin 200 mg

NCT03315143

10,584

68.3 (8.1)

5830 (55.1)

1.3

60 (10.4)

44.5 (10.6)

3283 (31.0%) patients with history of HF.

SOLOIST-WHF, 2020 [25]

Sotagliflozin 200 mg

NCT03521934

1222

68.9 (9.2)

810 (66.3)

0.77

35 (13.3)

50.0 (17.0)

All patients with HF, 321 (99.1%) patients with non-advanced HF.

VERTIS CV, 2020 [31]

Ertugliflozin 5 mg

NCT01986881

5499

64.4 (8.0)

3851 (70.0)

3.5

NA

75.9 (20.8)

All patients with history of CAD.

Yale et al, 2013 [38]

Canagliflozin 100 mg

NCT01064414

180

68.8 (8.3)

115 (63.8)

1

NA

40.1 (6.8)

100 (56.1%) patients with history of CAD.